Celltrion Strengthens European Biosimilar Leadership with Remsima Liquid Formulation Launch
March 11, 2026 – Celltrion today announced the European launch of a liquid formulation of Remsima (infliximab), a move designed to solidify its position in the infliximab biosimilar market. The formulation, protected by registered patents held exclusively by Celltrion globally, aims to enhance product competitiveness and expand market impact by addressing clinical needs for more convenient administration.
Nordic Success and Market Share Gains
Celltrion’s Nordic affiliate has already achieved early success, securing contracts for the Remsima intravenous (IV) liquid formulation through national tenders in Denmark and Norway. Sales in Norway commenced immediately following the tender award, with supply secured through January 2028. This is projected to capture approximately 35% of the infliximab IV market share in Norway.
Addressing Clinical Needs with Innovative Formulation
The Remsima liquid formulation complements the existing Remsima IV (100 mg lyophilized formulation) and Remsima SC, offering a broader range of treatment options. European clinical settings have shown a demand for multi-dose liquid formulations that simplify storage and preparation processes. The 350 mg liquid formulation directly responds to these needs.
Efficiency and Cost Savings for Healthcare Institutions
Healthcare institutions are expected to benefit from administrative and cost efficiencies with the new liquid formulation. Compared to the lyophilized version, the liquid formulation reduces preparation time by approximately 50% and lowers labor and consumable costs during drug preparation by around 20%. Storage space and associated costs can be reduced by up to 70%, generating significant interest across Europe.
Patent Protection and Portfolio Expansion
Celltrion has filed and completed patent registrations for the Remsima liquid formulation in most European countries, including key EU5 markets like the UK, Germany, and France. As the only infliximab product currently available in a liquid formulation, Remsima’s competitive advantage is expected to grow.
A Complete Infliximab Portfolio
Following the development of the world’s first infliximab subcutaneous (SC) formulation, Celltrion now offers a complete portfolio of infliximab IV (both lyophilized and liquid) and SC formulations. This comprehensive lineup is intended to build trust in the Remsima brand, increase prescriptions for both IV and SC versions, and improve profitability.
European Expansion Plans
Starting in the Nordic region, Celltrion plans to expand the launch of the Remsima liquid formulation throughout Europe this year, including France, the Netherlands, and the Czech Republic. According to market research firm IQVIA, the Remsima portfolio (IV and SC) held the leading position in infliximab prescriptions in Europe with a 68% market share as of the third quarter of last year.
“As trust in Celltrion continues to build in the European biosimilar market, the Remsima liquid formulation reflects clinical needs and has demonstrated its competitiveness by securing tender wins immediately after launch,” said Seung-doo Baek, Head of Celltrion’s Nordic affiliate. “Going forward, we will continue field-focused sales and marketing activities to provide better treatment options for patients and healthcare professionals in Europe while further expanding prescriptions.”